It's wrong to equate Drs. Musella, Liau, Ashkan, etc. or investors like Bigger as speaking for the company. They are not employed by the company in this capacity, but certainly they're either involved clinically, medically, or as investors and they're willing to state their opinion.
As for those who speak for the company, they've provided some guidance, but they've largely been silenced by the quiet period. I suspect that when the quiet period ends we'll be getting a lot of information from Dave, but even more from L.P. as she's invited to appear at many brokerage and Institutional conferences. In Dave's position, I don't know that he can tell individual investors anything that hasn't been shared with others, but once the quiet period ends, questions to him that should be shared should be covered in some sort of release or conference by the company.
I would hope, and expect, that the biggest change will be in approaching a major exchange we'll start to act like a company that's already on the exchange. We'll have analysts following the company and each quarterly we'll webcast results and those analysts will be able to ask questions after the formal presentations. I don't know that it's a requirement of Nasdaq or NYSE companies, but I don't know of any that don't do it.
We're approaching two years since the quiet period was established, that's longer than any I've seen from others, but the company did establish what they were doing, so it's understandable, even if you disagree with it. Clearly in the past two months the company has permitted greater discussion of the trial, but far from everything has been discussed.
I'm still of the belief that they want the Journal before the Annual Meeting, however if they fail to get it in the next couple weeks I believe they'll announce the meeting and the official TLD statement as well, that way by the meeting, whether they get the Journal or not, they can discuss what they've done over nearly the last two years. They may not be able to go deeper into the trial than what's been presented in the peer reviewed conferences, but they'll be able to discuss where things stand wrt approaching the regulators, and that's really what matters the most. The anticipation of approval in the not to distant future should be even bigger than whatever can be said in a Journal.
Gary
